President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Patient PortalAdult ClinicPediatricsEye CareMake an AppointmentBillingInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Studies for People with Type 1 Diabetes (insulin-dependent or IDDM)

Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients with Type 1 Diabetes

Description: This study is designed to test if the drug Bydureon® (exenatide-ER) improves blood glucose control in patients with type 1 diabetes. Bydureon® is currently approved only for patients with type 2 diabetes. However, there is reason to believe that it may improve glucose levels in some type 1 diabetes patients, possibly by increasing insulin secretion and/or suppressing levels of the hormone glucagon.

Bydureon® or a placebo will be given via subcutaneous injection once a week for 6 months, followed by 6 months of additional monitoring. Change in HbA1C level, insulin secretion in response to a mixed-meal tolerance test, changes in insulin requirement, and glycemic variability will be measured during the study. Participation in the study will involve periodic lab tests and follow-up visits at the Joslin Diabetes Center.

Recruitment: Seeking eligible individuals ages 18-60 who: 1) were diagnosed with type 1 diabetes at least 2 years ago; 2) require insulin of ≤0.90 units/kg/day; 3) have not had ketoacidosis in the last 6 months; 4) have an HbA1C of ≤9.0%.

Contact: Mary Ellen Migre at 617-309-4148 or

(CHS #2015-26)

TrialNet Natural History Study for the Prevention of Type 1 Diabetes

Description: The study aims to identify youth and adults at risk for type 1 diabetes by testing for diabetes-related antibodies in relatives of people with type 1 diabetes.  It involves a single blood test.  People who test positive will be eligible for further testing and may be eligible to participate in prevention trials.

Recruitment: Parents, children, & siblings, ages 1-45, and cousins, grandchildren, nieces, & nephews, ages 1-20, of people with type 1 diabetes.

Contact: Sarah Szubowicz at (617) 309-4493 or

(CHS #03-33)

Monitoring Autoimmunity in Diabetes

Description: The purpose of the "Monitoring Autoimmunity in Diabetes" study is to look at changes in the body that may occur with the development of type 1 diabetes. The samples taken as part of this study will be used to look at various genes, cells, and factors, which may be associated with type 1 diabetes and the immune system. These will be used to study why some people are at higher risk for developing diabetes and what happens to the immune system with the development of the disease. Participants may also qualify and be asked to participate in a separate clinical study that uses a novel magnetic resonance imaging (MRI) technique to noninvasively image insulitis (the destructive process in the pancreas that leads to loss of insulin production).

Recruitment: Seeking controls (no history of type 1 diabetes) and persons recently diagnosed with type 1 diabetes (within last 6 months). Must be 18 years or older.

Contact: Sarah Szubowicz at (617) 309-4493 or

(CHS #2010-27)

Fast Progression to Diabetic Complications (Progressor Study)

Description: The purpose of this study is to associate identified factors with the protection from the progression of eye and kidney complications related to type 1 diabetes. These will be studied in individuals with type 1 diabetes who have experienced rapid progression to severe diabetic retinopathy and/or diabetic nephropathy, despite good glycemic control. By studying these factors, researchers can subsequently confirm and potentially identify other factors that provide protection from eye and kidney complications.

Recruitment:Patients with type 1 diabetes with HbA1c ≤7.5%, who have progressed to severe non-proliferative diabetic retinopathy in 15 years or less, or to diabetic nephropathy (eGFR <60 ml/min/1.73 m2) within 20 years.

Contact: Stephanie D’Eon at (617) 309-4532 or stephanie.d'

(CHS# 2013-03)

Page last updated: October 28, 2016